by Rod Raynovich | Mar 23, 2011 | BIOgraph
But Cardiovascular Biomarker Indicates Anti-Inflammatory Activity For XOMA052 Xoma (XOMA $3.55) said its lead Type 2 diabetes drug-XOMA052- in a Phase 2b study failed to meet its main goal of lowering blood glucose levels. The trial failed to achieve its primary...